Log in

NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News

$1.17
0.00 (0.00 %)
(As of 01/27/2020 07:08 AM ET)
Today's Range
$1.11
Now: $1.17
$1.19
50-Day Range
$0.99
MA: $1.15
$1.25
52-Week Range
$0.52
Now: $1.17
$5.38
Volume582,114 shs
Average Volume574,101 shs
Market Capitalization$54.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.50 million
Book Value$0.26 per share

Profitability

Net Income$-51,150,000.00
Net Margins-851.71%

Miscellaneous

Employees153
Market Cap$54.62 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) issued its quarterly earnings results on Monday, November, 18th. The medical equipment provider reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The medical equipment provider earned $1.68 million during the quarter, compared to analysts' expectations of $2.17 million. T2 Biosystems had a negative net margin of 851.71% and a negative return on equity of 1,263.80%. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for T2 Biosystems.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3-3 million, compared to the consensus revenue estimate of $3.67 million.

What price target have analysts set for TTOO?

7 analysts have issued 1-year price targets for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' share price to reach $5.63 in the next twelve months. This suggests a possible upside of 381.1% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/15/2019)
  • 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019)

Has T2 Biosystems been receiving favorable news coverage?

News stories about TTOO stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. T2 Biosystems earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for T2 Biosystems.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a drop in short interest in January. As of January 15th, there was short interest totalling 3,540,000 shares, a drop of 17.3% from the December 31st total of 4,280,000 shares. Based on an average daily trading volume, of 594,000 shares, the days-to-cover ratio is currently 6.0 days. Approximately 9.0% of the shares of the company are sold short. View T2 Biosystems' Current Options Chain.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 59)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 59)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
  • Dr. Tyler E. Jacks, Co-Founder (Age 58)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $1.17.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $54.62 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com/.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  625
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel